Internal Medicine News (08/01/2012) Tucker, Miriam E.
An analysis of data from administrative claims associated with adults with type 2 diabetes has revealed that the daily use of glargine brings about similar clinical outcomes as the use of liraglutide. One of the findings of the analysis, which were presented at the American Diabetes Association's annual scientific sessions, was that those who took glargine and those who took liraglutide experienced similar reductions in HbA1c levels compared to baseline. HbA1c levels fell from 8.96 percent to 7.94 percent in patients who took glargine for one year, while those who took liraglutide for the same amount of time saw their HbA1c levels drop from 8.76 percent to 7.81 percent. But the analysis showed that there was a significant difference in the cost of the two treatments, with glargine coming in at a lower cost than liraglutide.